-
x
x
bid
ask
05:01 AM
Bearish
11
Bullish
30
sentiment
day range
52 week range
Prev Close
Open
Low
High
Volume0.00
Avg. Volume0.00
Market Cap0.00
Inst. Own
Beta
Short Ratio
Div & Yield /
EPS
P/E
1yr Target
50day MA
200day MA
CNQ.TO
Canadian Natural Resources Limited
106.52
04:00 PM
+
0.84
0.79%
G.TO
Augusta Gold Corp.
0.96
03:59 PM
-
0.07
6.80%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.25
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2533.05
05:59 AM
-
46.55
1.80%
600690.SS
Haier Smart Home Co., Ltd.
28.35
03:00 AM
-
0.08
0.28%
0700.HK
Tencent Holdings Limited
348.40
04:08 AM
+
9.00
2.65%
1101.TW
Taiwan Cement Corp.
31.80
01:30 AM
-
0.20
0.62%
20MICRONS.NS
20 Microns Limited
162.85
05:59 AM
+
5.90
3.76%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
5 Biotech Acquisition Targets To Accumulate In 2024 | seekingalpha.com • |
AstraZeneca and Alexion working with FDA on US label expansion for Ultomiris | proactiveinvestors.co.uk • |
AstraZeneca to pay US$775mln to settle Alexion patent dispute | proactiveinvestors.co.uk • |
AstraZeneca PLC boosted by Alexion acquisition; five newly-minted blockbusters join its medicine cabinet | proactiveinvestors.co.uk • |
AstraZeneca's takeover of Alexion the highlight of a quieter quarter for mergers & acquisitions | proactiveinvestors.co.uk • |
Jeremy Grantham's Firm Profits From Wave of Acquisitions in 3rd Quarter | gurufocus.com • |
Profile
...
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. The company was incorporated in 1992 and is based in Boston, Massachusetts with an additional office in Switzerland. As of July 21, 2021, Alexion Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca PLC.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2021-07-29 | 2021-06 | 3.47 | N/A | N/A | N/A |
2021-04-30 | 2021-03 | 3.08 | N/A | N/A | N/A |
2021-02-04 | 2020-12 | 2.5 | N/A | N/A | N/A |
2020-10-29 | 2020-09 | 2.59 | N/A | N/A | N/A |
2020-07-30 | 2020-06 | 2.55 | N/A | N/A | N/A |
2020-05-06 | 2020-03 | 2.7 | N/A | N/A | N/A |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2021-03-23 | SVB Leerink | Downgrade | Outperform | Market Perform |
2021-02-05 | SVB Leerink | Upgrade | Outperform | |
2021-01-08 | Raymond James | Downgrade | Outperform | Market Perform |
2020-12-16 | Truist Securities | Downgrade | Buy | Hold |
2020-12-15 | Citigroup | Downgrade | Buy | Neutral |
2020-12-14 | Credit Suisse | Downgrade | Outperform | Neutral |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-07-13 | BAZARKO DANIEL | Officer | 60.21K | Stock Award(Grant) |
2021-07-13 | CARINO TANISHA | Officer | 59.23K | Stock Award(Grant) |
2021-07-13 | CHINIARA ELLEN V | Officer | 116.85K | Stock Award(Grant) |
2021-05-19 | COUGHLIN CHRISTOPHER J | Director | 42.35K | Stock Award(Grant) |
2021-05-19 | FRIEDMAN PAUL A | Director | 12.84K | Stock Award(Grant) |
2021-07-13 | GOFF BRIAN | Officer | 150.83K | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2021-03-30 | Vanguard Group, Inc. (The) | 19.57M | 2.99B | 8.85% |
2021-03-30 | Blackrock Inc. | 17.55M | 2.68B | 7.94% |
2021-03-30 | State Street Corporation | 9.88M | 1.51B | 4.47% |
2021-03-30 | Pentwater Capital Management Lp | 4.29M | 655.87M | 1.94% |
2021-03-30 | Adage Capital Partners GP L.L.C. | 4.24M | 648.70M | 1.92% |
2021-03-30 | Baker Brothers Advisors, LLC | 3.99M | 610.62M | 1.81% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2021-03-30 | Vanguard Total Stock Market Index Fund | 5.88M | 899.80M | 2.66% |
2021-03-30 | Vanguard 500 Index Fund | 4.50M | 688.42M | 2.04% |
2021-06-29 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 2.86M | 526.21M | 1.30% |
2021-06-29 | SPDR S&P 500 ETF Trust | 2.28M | 418.42M | 1.03% |
2021-05-30 | Fidelity 500 Index Fund | 2.05M | 362.33M | 0.93% |
2021-03-30 | Vanguard Institutional Index Fund-Institutional Index Fund | 1.76M | 268.57M | 0.79% |
Split
...
Split | Date |
---|---|
2 : 1 | 2011-05-23 |
2 : 1 | 2008-08-25 |
This topic has been deleted. Only users with topic management privileges can see it.
-
5 Biotech Acquisition Targets To Accumulate In 2024
seekingalpha.com • -
AstraZeneca and Alexion working with FDA on US label expansion for Ultomiris
proactiveinvestors.co.uk • -
AstraZeneca to pay US$775mln to settle Alexion patent dispute
proactiveinvestors.co.uk • -
AstraZeneca PLC boosted by Alexion acquisition; five newly-minted blockbusters join its medicine cabinet
proactiveinvestors.co.uk • -
AstraZeneca's takeover of Alexion the highlight of a quieter quarter for mergers & acquisitions
proactiveinvestors.co.uk • -
AstraZeneca eyes big jump in revenue after Alexion acquisition
proactiveinvestors.co.uk • -
AstraZeneca says Alexion receives recommendation to use rare blood disorder drug in kids
proactiveinvestors.co.uk • -
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
investorplace.com • -
AstraZeneca gets final go-ahead for £27.5bn Alexion acquisition
proactiveinvestors.co.uk • -
7 Low Price-to-Book Stocks Worth Buying in July
zacks.com • -
AstraZeneca receives EU clearance for £27.5bn Alexion acquisition
proactiveinvestors.co.uk • -
Apellis Pharmaceuticals Goes After Alexion Blood Disorder Drugs
gurufocus.com • -
AstraZeneca to appoint new chief financial officer when Alexion acquisition completes
proactiveinvestors.co.uk • -
AstraZeneca names Alexion's Sarin as new finance chief
reuters.com • -
AstraZeneca prices £691mln bond offering linked to Alexion Pharmaceuticals, Inc. acquisition
proactiveinvestors.co.uk • -
AstraZeneca £27.5bn acquisition of Alexion under investigation by competition watchdog
proactiveinvestors.co.uk • -
Alexion Shareholders Approve Acquisition by AstraZeneca
businesswire.com • -
Elfun Trusts' Top 5 Trades of the 1st Quarter
gurufocus.com • -
Recap: Alexion Pharmaceuticals Q1 Earnings
benzinga.com • -
Earnings Outlook For Alexion Pharmaceuticals
benzinga.com • -
Alexion to Report First Quarter 2021 Results on Monday, May 3, 2021
businesswire.com • -
AstraZeneca receives green light from US regulators for Alexion acquisition
proactiveinvestors.co.uk • -
John Paulson's Top 5 Buys of the 4th Quarter
gurufocus.com • -
5 Finest PEG Stocks for GARP Investors
zacks.com • -
Alexion Pharma pauses further enrollment in COVID-19 drug study
marketwatch.com • -
3 Great Stocks You Can Buy on Sale
fool.com • -
ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion
zacks.com • -
Biotech ETFs surge on vaccine rollout, Alexion-AstraZeneca tie-up
marketwatch.com •